Johan A Maertens1, Galia Rahav2, Dong-Gun Lee3, Alfredo Ponce-de-León4, Isabel Cristina Ramírez Sánchez5, Nikolay Klimko6, Anne Sonet7, Shariq Haider8, Juan Diego Vélez9, Issam Raad10, Liang-Piu Koh11, Meinolf Karthaus12, Jianying Zhou13, Ronen Ben-Ami14, Mary R Motyl15, Seongah Han16, Anjana Grandhi17, Hetty Waskin18. 1. Department of Microbiology, Immunology, and Transplantation, KU Leuven, Leuven, Belgium; Department of Hematology, University Hospitals Leuven, Leuven, Belgium. Electronic address: johan.maertens@uzleuven.be. 2. Sheba Medical Center, Tel-Hashomer, Ramat Gan, Israel; Sackler School of Medicine, Tel Aviv University, Ramat Gan, Israel. 3. Division of Infectious Diseases, Department of Internal Medicine, The Catholic University of Korea, Seoul, South Korea. 4. Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, México. 5. Hospital Pablo Tobón Uribe, Universidad de Antioquia, Medellín, Colombia. 6. Department of Clinical Mycology, Allergy and Immunology, North Western State Medical University, St Petersburg, Russia. 7. CHU UCL Namur, Université Catholique de Louvain, Yvoir, Belgium. 8. Juravinski Hospital and Cancer Center, McMaster University, Hamilton, ON, Canada. 9. Fundación Valle del Lili, Cali, Colombia. 10. The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 11. National University Cancer Institute, National University Health System, Singapore. 12. Klinikum Neuperlach, Munich, Germany. 13. Department of Respiratory Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. 14. Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 15. Department of Clinical Microbiology, Merck & Co, Inc, Kenilworth, NJ, USA. 16. Department of Diabetes/NASH, Merck & Co, Inc, Kenilworth, NJ, USA. 17. Department of Biostatistics, Merck & Co, Inc, Kenilworth, NJ, USA. 18. Department of Infectious Disease, Merck & Co, Inc, Kenilworth, NJ, USA.
Abstract
BACKGROUND:Voriconazole has been recommended as primary treatment for patients with invasive aspergillosis. Intravenous and tablet formulations of posaconazole that have improved systemic absorption could be an effective alternative to voriconazole. We aimed to assess non-inferiority of posaconazole to voriconazole for the primary treatment of invasive aspergillosis. METHODS: We did a randomised, prospective, double-blind, double-dummy, controlled trial comparing posaconazole (intravenous or oral posaconazole 300 mg twice on day 1, followed by 300 mg once a day for days 2-84) with voriconazole (6 mg/kg intravenous or 300 mg oral twice on day 1 followed by 4 mg/kg intravenously or 200 mg orally twice a day for days 2-84) for 12 weeks or less in the primary treatment of invasive aspergillosis. Participants were from 91 study sites in 26 countries, were aged 13 years or older, weighed at least 40 kg, and met criteria for proven, probable, or possible fungal disease. Participants were randomly assigned (1:1) via a computer-generated randomisation schedule with stratification by risk status. The primary endpoint was cumulative all-cause mortality up until day 42 in the intention-to-treat (ITT) population (defined as randomly assigned participants who received ≥1 dose of study drug), with a 10% non-inferiority margin. The ITT population was also evaluated for safety. This study is registered with ClinicalTrials.gov, NCT01782131, and EudraCT, 2011-003938-14. FINDINGS: Between Oct 25, 2013, and Sept 10, 2019, of 653 individuals assessed for eligibility, 575 ITT participants were randomly assigned and received one or more doses of study drug (n=288 [50%] posaconazole, n=287 [50%] voriconazole). Mortality up until day 42 was 15% (44 of 288) in the posaconazole group and 21% (59 of 287) in the voriconazole group (treatment difference -5·3% [95% CI -11·6 to 1·0]; p<0·0001). Mortality up until day 42 in the full-analysis-set subpopulation (ITT participants with proven or probable invasive aspergillosis) supported this conclusion: 31 (19%) of 163 participants in the posaconazole group and 32 (19%) of 171 participants in the voriconazole group (treatment difference 0·3% [95% CI -8·2 to 8·8]). The most frequently reported treatment-related adverse events (incidence >3%) were increased aspartate aminotransferase (AST) or alanine aminotransferase (ALT), nausea, hypokalaemia, and vomiting in the posaconazole group and increased ALT, AST, or alkaline phosphatase, hallucination, increased γ-glutamyltransferase peptidase, nausea, and blurred vision in the voriconazole group. The overall incidence of treatment-related adverse event rates in the ITT population was 30% for posaconazole and 40% for voriconazole (treatment difference -10·2% [95% CI -17·9 to -2·4]). INTERPRETATION:Posaconazole was non-inferior to voriconazole for all-cause mortality up until day 42 in participants with invasive aspergillosis. Posaconazole was well tolerated, and participants had fewer treatment-related adverse events than in the voriconazole group. This study supports the use of posaconazole as a first-line treatment for the condition. FUNDING: Merck Sharp & Dohme, a subsidiary of Merck & Co, Inc.
RCT Entities:
BACKGROUND:Voriconazole has been recommended as primary treatment for patients with invasive aspergillosis. Intravenous and tablet formulations of posaconazole that have improved systemic absorption could be an effective alternative to voriconazole. We aimed to assess non-inferiority of posaconazole to voriconazole for the primary treatment of invasive aspergillosis. METHODS: We did a randomised, prospective, double-blind, double-dummy, controlled trial comparing posaconazole (intravenous or oral posaconazole 300 mg twice on day 1, followed by 300 mg once a day for days 2-84) with voriconazole (6 mg/kg intravenous or 300 mg oral twice on day 1 followed by 4 mg/kg intravenously or 200 mg orally twice a day for days 2-84) for 12 weeks or less in the primary treatment of invasive aspergillosis. Participants were from 91 study sites in 26 countries, were aged 13 years or older, weighed at least 40 kg, and met criteria for proven, probable, or possible fungal disease. Participants were randomly assigned (1:1) via a computer-generated randomisation schedule with stratification by risk status. The primary endpoint was cumulative all-cause mortality up until day 42 in the intention-to-treat (ITT) population (defined as randomly assigned participants who received ≥1 dose of study drug), with a 10% non-inferiority margin. The ITT population was also evaluated for safety. This study is registered with ClinicalTrials.gov, NCT01782131, and EudraCT, 2011-003938-14. FINDINGS: Between Oct 25, 2013, and Sept 10, 2019, of 653 individuals assessed for eligibility, 575 ITT participants were randomly assigned and received one or more doses of study drug (n=288 [50%] posaconazole, n=287 [50%] voriconazole). Mortality up until day 42 was 15% (44 of 288) in the posaconazole group and 21% (59 of 287) in the voriconazole group (treatment difference -5·3% [95% CI -11·6 to 1·0]; p<0·0001). Mortality up until day 42 in the full-analysis-set subpopulation (ITT participants with proven or probable invasive aspergillosis) supported this conclusion: 31 (19%) of 163 participants in the posaconazole group and 32 (19%) of 171 participants in the voriconazole group (treatment difference 0·3% [95% CI -8·2 to 8·8]). The most frequently reported treatment-related adverse events (incidence >3%) were increased aspartate aminotransferase (AST) or alanine aminotransferase (ALT), nausea, hypokalaemia, and vomiting in the posaconazole group and increased ALT, AST, or alkaline phosphatase, hallucination, increased γ-glutamyltransferase peptidase, nausea, and blurred vision in the voriconazole group. The overall incidence of treatment-related adverse event rates in the ITT population was 30% for posaconazole and 40% for voriconazole (treatment difference -10·2% [95% CI -17·9 to -2·4]). INTERPRETATION:Posaconazole was non-inferior to voriconazole for all-cause mortality up until day 42 in participants with invasive aspergillosis. Posaconazole was well tolerated, and participants had fewer treatment-related adverse events than in the voriconazole group. This study supports the use of posaconazole as a first-line treatment for the condition. FUNDING: Merck Sharp & Dohme, a subsidiary of Merck & Co, Inc.
Authors: Lore Vanderbeke; Nico A F Janssen; Roger J M Brüggemann; Joost Wauters; Dennis C J J Bergmans; Marc Bourgeois; Jochem B Buil; Yves Debaveye; Pieter Depuydt; Simon Feys; Greet Hermans; Oscar Hoiting; Ben van der Hoven; Cato Jacobs; Katrien Lagrou; Virginie Lemiale; Piet Lormans; Johan Maertens; Philippe Meersseman; Bruno Mégarbane; Saad Nseir; Jos A H van Oers; Marijke Reynders; Bart J A Rijnders; Jeroen A Schouten; Isabel Spriet; Karin Thevissen; Arnaud W Thille; Ruth Van Daele; Frank L van de Veerdonk; Paul E Verweij; Alexander Wilmer Journal: Intensive Care Med Date: 2021-05-29 Impact factor: 17.440
Authors: Monica A Slavin; Yee-Chun Chen; Catherine Cordonnier; Oliver A Cornely; Manuel Cuenca-Estrella; J Peter Donnelly; Andreas H Groll; Olivier Lortholary; Francisco M Marty; Marcio Nucci; John H Rex; Bart J A Rijnders; George R Thompson; Paul E Verweij; P Lewis White; Ruth Hargreaves; Emma Harvey; Johan A Maertens Journal: J Antimicrob Chemother Date: 2021-12-24 Impact factor: 5.790
Authors: Paul E Verweij; Roger J M Brüggemann; Elie Azoulay; Matteo Bassetti; Stijn Blot; Jochem B Buil; Thierry Calandra; Tom Chiller; Cornelius J Clancy; Oliver A Cornely; Pieter Depuydt; Philipp Koehler; Katrien Lagrou; Dylan de Lange; Cornelia Lass-Flörl; Russell E Lewis; Olivier Lortholary; Peter-Wei Lun Liu; Johan Maertens; M Hong Nguyen; Thomas F Patterson; Bart J A Rijnders; Alejandro Rodriguez; Thomas R Rogers; Jeroen A Schouten; Joost Wauters; Frank L van de Veerdonk; Ignacio Martin-Loeches Journal: Intensive Care Med Date: 2021-06-23 Impact factor: 17.440